PMID- 23840142
OWN - NLM
STAT- MEDLINE
DCOM- 20140217
LR  - 20220408
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 25
DP  - 2013 Jul 7
TI  - Polydatin attenuated food allergy via store-operated calcium channels in mast 
      cell.
PG  - 3980-9
LID - 10.3748/wjg.v19.i25.3980 [doi]
AB  - AIM: To investigate the effect of polydatin (PD), a resveratrol glucoside, on 
      mast cell degranulation and anti-allergic activity. METHODS: After the rats were 
      orally sensitized with ovalbumin (OVA) for 48 d and underwent PD treatment for 4 
      d, all the rats were stimulated by 100 mg/mL OVA for 24 h and then sacrificed for 
      the following experiments. The small intestines from all the groups were prepared 
      for morphology examination by hematoxylin and eosin staining. We also used a 
      smooth muscle organ bath to evaluate the motility of the small intestines. The 
      OVA-specific immunoglobulin E (IgE) production and interleukin-4 (IL-4) levels in 
      serum or supernatant of intestinal mucosa homogenates were analyzed by 
      enzyme-linked immunosorbent assay (ELISA). Using toluidine blue stain, the 
      activation and degranulation of isolated rat peritoneal mast cells (RPMCs) were 
      analyzed. Release of histamine from RPMCs was measured by ELISA, and regulation 
      of PD on intracellular Ca(2+) mobilization was investigated by probing 
      intracellular Ca(2+) with fluo-4 fluorescent dye, with the signal recorded and 
      analyzed. RESULTS: We found that intragastric treatment with PD significantly 
      reduced loss of mucosal barrier integrity in the small intestine. However, 
      OVA-sensitization caused significant hyperactivity in the small intestine of 
      allergic rats, which was attenuated by PD administration by 42% (1.26 +/- 0.13 g vs 
      OVA 2.18 +/- 0.21 g, P < 0.01). PD therapy also inhibited IgE production (3.95 +/- 
      0.53 ng/mL vs OVA 4.53 +/- 0.52 ng/mL, P < 0.05) by suppressing the secretion of 
      Th2-type cytokine, IL-4, by 34% (38.58 +/- 4.41 pg/mL vs OVA 58.15 +/- 6.24 pg/mL, P 
      < 0.01). The ratio of degranulated mast cells, as indicated by vehicles (at least 
      five) around the cells, dramatically increased in the OVA group by 5.5 fold 
      (63.50% +/- 15.51% vs phosphate-buffered saline 11.15% +/- 8.26%, P < 0.001) and fell 
      by 65% after PD treatment (21.95% +/- 4.37% vs OVA 63.50% +/- 15.51%, P < 0.001). PD 
      mediated attenuation of mast cell degranulation was further confirmed by 
      decreased histamine levels in both serum (5.98 +/- 0.17 vs OVA 6.67 +/- 0.12, P < 
      0.05) and intestinal mucosa homogenates (5.83 +/- 0.91 vs OVA 7.35 +/- 0.97, P < 
      0.05). Furthermore, we demonstrated that administration with PD significantly 
      decreased mast cell degranulation due to reduced Ca(2+) influx through 
      store-operated calcium channels (SOCs) (2.35 +/- 0.39 vs OVA 3.51 +/- 0.38, P < 
      0.01). CONCLUSION: Taken together, our data indicate that PD stabilizes mast 
      cells by suppressing intracellular Ca(2+) mobilization, mainly through inhibiting 
      Ca(2+) entry via SOCs, thus exerting a protective role against OVA-sensitized 
      food allergy.
FAU - Yang, Bo
AU  - Yang B
AD  - Allergy Branch of the State Key Laboratory of Respiratory Disease, School of 
      Medicine, Shenzhen University, Shenzhen 518060, Guangdong Province, China.
FAU - Li, Jian-Jie
AU  - Li JJ
FAU - Cao, Ji-Juan
AU  - Cao JJ
FAU - Yang, Cheng-Bin
AU  - Yang CB
FAU - Liu, Jie
AU  - Liu J
FAU - Ji, Qiong-Mei
AU  - Ji QM
FAU - Liu, Zhi-Gang
AU  - Liu ZG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Calcium Channels)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glucosides)
RN  - 0 (Stilbenes)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 820484N8I3 (Histamine)
RN  - 9006-59-1 (Ovalbumin)
RN  - SY7Q814VUP (Calcium)
RN  - XM261C37CQ (polydatin)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Calcium Channels/*drug effects/*physiology
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/pharmacology/therapeutic use
MH  - Female
MH  - Food Hypersensitivity/metabolism/physiopathology/*prevention & control
MH  - Glucosides/*pharmacology/*therapeutic use
MH  - Histamine/metabolism
MH  - Immunoglobulin E/blood
MH  - Interleukin-4/blood
MH  - Intestine, Small/drug effects/metabolism/physiopathology
MH  - Mast Cells/*drug effects/metabolism/pathology
MH  - Ovalbumin/adverse effects
MH  - Rats
MH  - Rats, Inbred BN
MH  - Stilbenes/*pharmacology/*therapeutic use
PMC - PMC3703184
OTO - NOTNLM
OT  - Ca2+
OT  - Food allergy
OT  - Mast cells
OT  - Polydatin
OT  - Store-operated calcium channels
EDAT- 2013/07/11 06:00
MHDA- 2014/02/18 06:00
PMCR- 2013/07/07
CRDT- 2013/07/11 06:00
PHST- 2013/02/22 00:00 [received]
PHST- 2013/04/10 00:00 [revised]
PHST- 2013/05/16 00:00 [accepted]
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2014/02/18 06:00 [medline]
PHST- 2013/07/07 00:00 [pmc-release]
AID - 10.3748/wjg.v19.i25.3980 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Jul 7;19(25):3980-9. doi: 10.3748/wjg.v19.i25.3980.